In this episode, Beth Sandy, MSN, CRNP provides her thoughts on key data presented at the 2022 ASCO annual conference relating to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). Findings covered include:

• Survival results after 3 years from the phase III Checkmate 9LA study of nivolumab and ipilimumab combined with 2 cycles of chemotherapy vs chemotherapy in previously untreated advanced NSCLC
• Updated survival and safety results after 5 years from the phase III Checkmate 227 study of nivolumab and ipilimumab vs chemotherapy in previously untreated advanced NSCLC, including assessment of a treatment-free interval
• Updated analysis from the phase III ATEZO-BRAIN trial of atezolizumab + carboplatin and pemetrexed in patients with advanced NSCLC with untreated brain metastases
• Updated overall response analysis from the phase II KEYNOTE-799 study of pembrolizumab with concurrent chemoradiation in unresectable, locally advanced stage III NSCLC
• Results from a phase II trial evaluating nivolumab plus ipilimumab vs nivolumab monotherapy following chemoradiation in unresectable stage III NSCLC
• Pathological complete response results from the phase II NADIM II study of nivolumab and chemotherapy vs chemotherapy in the neoadjuvant NSCLC setting

Presenter:

Beth Sandy, MSN, CRNP
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program:
https://bit.ly/39vuCHC